Cypherpunk Technologies Inc
Cypherpunk Technologies Inc. is a U.S.-based company that has shifted from its historical biopharmaceutical development work toward a digital asset treasury strategy centered on Zcash (ZEC). The company still retains its legacy research and development activities through its wholly owned subsidiary, Leap Therapeutics, Inc., including a clinical-stage oncology program and a preclinical cachexia program. In parallel, it is building a balance-sheet strategy around acquiring and holding ZEC and participating in the Zcash ecosystem. This makes the company unusual in that it combines a legacy biotech development platform with a crypto-treasury model focused on privacy-oriented digital assets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes the company’s oncology and cachexia antibody programs, clinical trials, and related development work.
Includes acquisition and holding of Zcash (ZEC) as a balance-sheet reserve asset and related treasury management.
Includes trading execution, custody, and storage infrastructure used to manage ZEC holdings through third parties.
Customers
The company does not currently sell approved pharmaceutical products, so it has no traditional commercial customer base in its legacy biotech business. Its biopharmaceutical work is aimed at cancer patients and, indirectly, the physicians, clinical investigators, and trial sites that support development programs. In its new digital asset strategy, the relevant counterparties are not end customers in the usual sense but rather exchanges, custodians, and market participants that facilitate ZEC acquisition and storage. Investors in the public company are also an important audience because the treasury strategy is intended to create exposure to ZEC through listed equity ownership.
Patients, physicians, and trial sites involved in evaluating sirexatamab and related cancer therapies.
Custodians and trading venues such as Gemini that execute purchases and hold ZEC on the company’s behalf.
Investors buying the listed shares for exposure to the company’s ZEC holdings and optionality on the legacy biotech pipeline.
Developers, community members, and protocol stakeholders that the company intends to engage with as an active ZEC holder.
Strategy
The company’s near-term strategy is to deploy capital into Zcash and build a public-market treasury vehicle around a privacy-focused digital asset. Management has explicitly stated that it intends to acquire and hold ZEC as the primary digital asset and to participate actively in the Zcash community. At the same time, it is preserving its legacy biopharmaceutical R&D through Leap Therapeutics, which keeps a potential clinical-development option alive. The strategy depends on building the operational, compliance, and custody infrastructure needed to manage digital assets while navigating volatile markets and evolving regulation.
The company is repositioning around Zcash holdings, so treasury execution is central to its new identity and valuation.
Custody, trading execution, security, and compliance are critical to protecting assets and executing the strategy safely.
The legacy oncology program may still create value and provides a non-crypto strategic asset base.
Geography
The company is headquartered in the United States and reports under U.S. GAAP, so its operating, financing, and regulatory exposure is primarily U.S.-based. Its digital asset treasury activities depend on U.S. market infrastructure, including Gemini as custodian and exchange execution venue. The company also faces U.S. federal and state regulatory scrutiny around digital assets, which can affect how it operates and how investors value the stock. Its legacy biotech activities are conducted through a U.S.-based corporate structure, although clinical development may involve external research sites and service providers.
Risks
The company faces substantial execution risk because it is shifting into a digital asset treasury model that requires new operational, technical, and compliance capabilities. ZEC is highly volatile, so changes in token price can quickly affect reported results and investor sentiment. The company is also dependent on Gemini for custody and trading execution, which creates counterparty and operational concentration risk. In addition, U.S. federal and state digital asset regulation remains unsettled, while the legacy biotech business still carries clinical development, funding, and going-concern risk because it has no approved product or product revenue.
- Failure to execute the digital asset treasury strategyImpact: HighLikelihood: High
The company is entering a new operating model that requires specialized skills, controls, and infrastructure it may not build in time.
Exposure - ZEC price volatilityImpact: HighLikelihood: High
The company plans to hold a significant portion of capital in ZEC, so market swings directly affect asset value and earnings.
Exposure: Balance sheet and net income
- Regulatory uncertainty for digital assetsImpact: HighLikelihood: High
Evolving SEC, Nasdaq, federal, and state rules could restrict or complicate the treasury strategy.
Exposure: Business model and listing compliance
- Custody and counterparty concentration at GeminiImpact: HighLikelihood: Medium
ZEC holdings are concentrated with a single custodian and the company has limited control over storage and execution systems.
Exposure: Asset security and operational continuity
- Clinical development and financing risk in biotechImpact: MediumLikelihood: High
The legacy R&D business has no approved products and depends on continued capital access and trial success.
Exposure: Pipeline value and liquidity
Accounting
Judgemental itemsQuoted market prices determine carrying value, so token volatility directly changes reported earnings and asset values.
Impact: Net income, balance sheet, and quarter-to-quarter comparability
Clinical and manufacturing services are often recognized before final invoices are received, requiring estimates.
Impact: Operating expenses and liabilities
Recognition depends on management judgment about recoverability and timing of reimbursements.
Impact: Assets and R&D expense presentation
Equity awards can materially affect reported compensation expense and dilution.
Impact: Operating expense and shareholder dilution
Similar listed companies
Publicly listed companies with a comparable business focus.
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
ZyVersa Therapeutics, Inc.
ZVSA · Pharmaceutical Preparations
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Zeta Network Group
ZNB · Finance Services
Zeta Network Group is a U.S.-based digital company organized around cryptocurrency mining through its wholly owned subsidiary, Model Queen Limited.
Zeo ScientifiX, Inc.
ZEOX · Biological Products, (No Diagnostic Substances)
Canton Strategic Holdings, Inc.
CNTN · Finance Services
Last updated: 24/09/2026